Prednisone

Overview

Prednisone is a glucocorticoid medication mostly used to suppress the immune system and decrease inflammation in conditions such as asthma, COPD, and rheumatologic diseases. It is also used to treat high blood calcium due to cancer and adrenal insufficiency along with other corticosteroids. It is taken by mouth.[1] WP

Common side effects may include cataracts, bone loss, easy bruising, muscle weakness, and thrush. Other side effects include weight gain, swelling, high blood sugar, increased risk of infection, and psychosis. It is generally considered safe in pregnancy and low doses appear to be safe while the user is breastfeeding. After prolonged use, prednisone must be stopped gradually.[1][2][3] WP

Prednisone is a prodrug and must be converted to prednisolone by the liver before it becomes active. Prednisolone then binds to glucocorticoid receptors, activating them and triggering changes in gene expression. These changes inhibit function and decrease the number of key leukocytes in the bloodstream.[2][4][5][6] WP

Prednisone was patented in 1954 and approved for medical use in the United States in 1955. Prednisone is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 38th most commonly prescribed medication in the United States, with more than 15 million prescriptions.[1][7–10] WP

Uses, dosage and effects

Medical uses

Prednisone is used for many different autoimmune diseases and inflammatory conditions, including asthma, gout, COPD, CIDP, rheumatic disorders, allergic disorders, ulcerative colitis and Crohn's disease, granulomatosis with polyangiitis, adrenocortical insufficiency, hypercalcemia due to cancer, thyroiditis, laryngitis, severe tuberculosis, hives, eczema, lipid pneumonitis, pericarditis, multiple sclerosis, nephrotic syndrome, sarcoidosis, to relieve the effects of shingles, lupus, myasthenia gravis, poison oak exposure, Ménière's disease, autoimmune hepatitis, giant cell arteritis, the Herxheimer reaction that is common during the treatment of syphilis, Duchenne muscular dystrophy, uveitis, and as part of a drug regimen to prevent rejection after organ transplant.[1][11][12] WP

Prednisone has also been used in the treatment of migraine headaches and cluster headaches and for severe aphthous ulcer. Prednisone is used as an antitumor drug.[13][14] WP

Prednisone is often also prescribed as a form of treatment for sudden sensorineural hearing loss (SSNHL).[15] WP

Prednisone can be used in the treatment of decompensated heart failure to increase renal responsiveness to diuretics, especially in heart failure patients with refractory diuretic resistance with large doses of loop diuretics. In terms of the mechanism of action for this purpose: prednisone, a glucocorticoid, can improve renal responsiveness to atrial natriuretic peptide by increasing the density of natriuretic peptide receptor type A in the renal inner medullary collecting duct, thereby inducing a potent diuresis.[16–22] WP⚠ A word may be missing here. It reads this way in the source too.

At high doses, it may be used to prevent rejection following an organ transplant.[1] WP

Risks and side effects

Side effects

Short-term side effects, as with all glucocorticoids, include high blood glucose levels (especially in patients with diabetes mellitus or on other medications that increase blood glucose, such as tacrolimus) and mineralocorticoid effects such as fluid retention. The mineralocorticoid effects of prednisone are minor, which is why it is not used in the management of adrenal insufficiency unless a more potent mineralocorticoid is administered concomitantly.[23] WP

It can also cause depression or depressive symptoms and anxiety in some individuals.[24][25] WP

Long-term side effects include Cushing's syndrome, steroid dementia syndrome, truncal weight gain, glaucoma and cataracts, diabetes mellitus type 2, and depression upon dose reduction or cessation. Long-term steroids can also increase the risk of osteoporosis, but research has found that few of these people were taking medications to protect bones. Prednisone also results in leukocytosis.[26–30] WP

Major

Source:[23] WP

• Steroid myopathy[23] WP
• Increased blood sugar for individuals with diabetes[23] WP
• Difficulty in regulating emotion[23] WP
• Difficulty in maintaining linear thinking[23] WP
• Weight gain due to increased appetite[23] WP
• Immunosuppression[23] WP
• Corticosteroid-induced lipodystrophy (moon face, central obesity)[23] WP
• Depression, mania, psychosis, or other psychiatric symptoms[31] WP
• Unusual fatigue or weakness[23] WP
• Mental confusion[23] WP
• Memory and attention dysfunction (steroid dementia syndrome)[23] WP
• Muscle atrophy[32] WP
• Blurred vision[23] WP
• Abdominal pain[23] WP
• Peptic ulcer[23] WP
• Painful hips or shoulders[23] WP
• Steroid-induced osteoporosis[23] WP
• Stretch marks[23] WP
• Osteonecrosis – same as avascular necrosis[23] WP
• Insomnia[23] WP
• Severe joint pain[23] WP
• Cataracts or glaucoma[23] WP
• Anxiety[23] WP
• Black stool[23] WP
• Stomach pain or bloating[23] WP
• Severe swelling[23] WP
• Mouth sores or dry mouth[23] WP
• Avascular necrosis[23] WP
• Hepatic steatosis[23] WP
• Hiccups and burping[23] WP
• Weakening and breakage of tendons[23] WP

Minor

Source:[23] WP

• Nervousness[23] WP
• Acne[23] WP
• Skin rash[23] WP
• Appetite gain[23] WP
• Hyperactivity[23] WP
• Increased thirst[23] WP
• Frequent urination[23] WP
• Diarrhea[23] WP
• Reduced intestinal flora[23] WP
• Leg pain/cramps[23] WP
• Sensitive teeth[23] WP
• Headache[23] WP
• Induced vomiting[23] WP

Dependency

Adrenal suppression will begin to occur if prednisone is taken for longer than seven days. Eventually, this may cause the body to temporarily lose the ability to manufacture natural corticosteroids (especially cortisol), which results in dependence on prednisone. For this reason, prednisone should not be abruptly stopped if taken for more than seven days; instead, the dosage should be gradually reduced. This weaning process may be over a few days if the course of prednisone is short but may take weeks or months if the patient had been on long-term treatment. Abrupt withdrawal may lead to an Addisonian crisis. For those on chronic therapy, alternate-day dosing may preserve adrenal function and thereby reduce side effects.[33][34] WP

Glucocorticoids act to inhibit feedback of both the hypothalamus, decreasing corticotropin-releasing hormone (CRH), and corticotrophs in the anterior pituitary gland, decreasing the amount of adrenocorticotropic hormone (ACTH). For this reason, glucocorticoid analogue drugs such as prednisone down-regulate the natural synthesis of glucocorticoids. This mechanism leads to dependence in a short time and can be dangerous if medications are withdrawn too quickly. The body must have time to begin synthesis of CRH and ACTH and for the adrenal glands to begin functioning normally again. WP

Prednisone may start to result in the suppression of the hypothalamic–pituitary–adrenal (HPA) axis if used at doses 7–10 mg or higher for several weeks. This is approximately equal to the amount of endogenous cortisol produced by the body every day. As such, the HPA axis starts to become suppressed and atrophy. If this occurs the patient should be tapered off prednisone slowly to give the adrenal gland enough time to regain its function and endogenous production of steroids. WP

Withdrawal

The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case-by-case basis, taking into consideration the underlying condition being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have: WP

• received more than 40 mg prednisone (or equivalent) daily for more than one week WP
• been given repeat doses in the evening WP
• received more than three weeks of treatment WP
• recently received repeated courses (particularly if taken for longer than three weeks) WP
• taken a short course within one year of stopping long-term therapy WP
• other possible causes of adrenal suppression WP

Systemic corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse who have received treatment for three weeks or less and who are not included in the patient groups described above. WP

During corticosteroid withdrawal, the dose may be reduced rapidly down to physiological doses (equivalent to prednisolone 7.5 mg daily) and then reduced more slowly. Assessment of the disease may be needed during withdrawal to ensure that relapse does not occur.[35] WP

Pharmacology

Pharmacology

Prednisone is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties. Prednisone is a prodrug; it is metabolised in the liver by 11-β-HSD to prednisolone, the active drug. Prednisone has no substantial biological effects until converted via hepatic metabolism to prednisolone.[36][37][38] WP

Pharmacokinetics

Prednisone is absorbed in the gastrointestinal tract and has a half-life of 2–3 hours. It has a volume of distribution of 0.4–1 L/kg. The drug is cleared by hepatic metabolism using cytochrome P450 enzymes. Metabolites are excreted in the bile and urine.[37][39] WP

Lodotra

"Lodotra" is the brand name of an oral formulation, which releases prednisone four hours after ingestion. It is indicated for rheumatoid arthritis with morning stiffness. Taken at 10 p.m., it releases the drug at around 2 a.m. The plasmic peak level is reached at 4 a.m., which is considered to be the optimal time for relieving morning stiffness. The drug was approved in the European Union, in January 2009.[40][41] WP

Research

Fibromyalgia

One small study found that prednisone was ineffective in the treatment of fibromyalgia and that there was actually a trend towards deterioration.[42][43][44] WP

History

History

The first isolation and structure identifications of prednisone and prednisolone were done in 1950 by Arthur Nobile. The first commercially feasible synthesis of prednisone was carried out in 1955 in the laboratories of Schering Corporation, which later became Schering-Plough Corporation, by Arthur Nobile and coworkers. They discovered that cortisone could be microbiologically oxidized to prednisone by the bacterium Corynebacterium simplex. The same process was used to prepare prednisolone from hydrocortisone.[45–49] WP

The enhanced adrenocorticoid activity of these compounds over cortisone and hydrocortisone was demonstrated in mice.[49] WP

Prednisone and prednisolone were introduced in 1955 by Schering and Upjohn, under the brand names Meticorten and Delta-Cortef, respectively.[50][51] WP

Chemistry

Formula

C21H26O5 PC

CAS number

53-03-2 PC

Molar mass (g/mol)

358.4 PC

IUPAC name (computed by PubChem)

(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione PC

SMILES

C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C PC

InChIKey

XOFYZVNMUHMLCC-ZPOLXVRWSA-N PC

PubChem CID

5865

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Prednisone Monograph for Professionals
2. Other Brunton L. Goodman & Gilman's the pharmacological basis of therapeutics. 2017
3. Other Prednisone Use During Pregnancy
4. Other Product Information Panafcort (prednisone) Panafcortelone (prednisolone). 11 July 2017
5. Journal / agency Buttgereit F, Gibofsky A. Delayed-release prednisone - a new approach to an old therapy. Expert Opinion on Pharmacotherapy. June 2013. doi:10.1517/14656566.2013.782001 · PMID 23594208
6. Other PMC, Europe. Europe PMC
7. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
8. Other World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. 2025
9. Other Top 300 of 2023
10. Other Prednisone Drug Usage Statistics, United States, 2014 - 2023
11. Other Autoimmune Hepatitis
12. Journal / agency LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 30 May 2014. PMID 31643719
13. Other Wackym PA, Snow JB. Ballenger's Otorhinolaryngology: Head and Neck Surgery. 2017
14. Journal / agency Antineoplastic Agents, Hormonal. 2009
15. Journal / agency Steroid Treatments Equally Effective Against Sudden Deafness. 22 May 2015
16. Journal / agency Riemer AD. Application of the newer corticosteroids to augment diuresis in congestive heart failure. The American Journal of Cardiology. April 1958. doi:10.1016/0002-9149(58)90120-6 · PMID 13520608
17. Journal / agency Newman DA. Reversal of intractable cardiac edema with prednisone. New York State Journal of Medicine. February 1959. PMID 13632954
18. Journal / agency Zhang H, Liu C, Ji Z, Liu G, Zhao Q, Ao YG, Wang L, Deng B, Zhen Y, Tian L, Ji L, Liu K. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. International Heart Journal. September 2008. doi:10.1536/ihj.49.587 · PMID 18971570
19. Journal / agency Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. The Canadian Journal of Cardiology. September 2007. doi:10.1016/s0828-282x(07)70840-1 · PMID 17876376 · PMC2651362
20. Journal / agency Liu C, Chen H, Zhou C, Ji Z, Liu G, Gao Y, Tian L, Yao L, Zheng Y, Zhao Q, Liu K. Potent potentiating diuretic effects of prednisone in congestive heart failure. Journal of Cardiovascular Pharmacology. October 2006. doi:10.1097/01.fjc.0000245242.57088.5b · PMID 17086096
21. Journal / agency Massari F, Mastropasqua F, Iacoviello M, Nuzzolese V, Torres D, Parrinello G. The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde?. The American Journal of Emergency Medicine. March 2012. doi:10.1016/j.ajem.2011.01.023 · PMID 21406321
22. Journal / agency Liu C, Chen Y, Kang Y, Ni Z, Xiu H, Guan J, Liu K. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure. The Journal of Pharmacology and Experimental Therapeutics. October 2011. doi:10.1124/jpet.111.184796 · PMID 21737535
23. Other Prednisone and other corticosteroids: Balance the risks and benefits
24. Other Prednisone Information
25. Journal / agency Prednisone
26. Journal / agency Wolkowitz OM, Lupien SJ, Bigler ED. The "steroid dementia syndrome": a possible model of human glucocorticoid neurotoxicity. Neurocase. June 2007. doi:10.1080/13554790701475468 · PMID 17786779
27. Other Steroids. April 2016
28. Journal / agency Polymyalgia rheumatica: treatment reviews are needed. 21 June 2022. doi:10.3310/nihrevidence_51304
29. Journal / agency Sokhal BS, Hider SL, Paskins Z, Mallen CD, Muller S. Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study. Rheumatology Advances in Practice. 2021. doi:10.1093/rap/rkab094 · PMID 34988356 · PMC8712242
30. Other Miller NR, Walsh FB, Hoyt WF. Walsh and Hoyt's Clinical Neuro-ophthalmology. 2005
31. Journal / agency De Bock M, Sienaert P. Corticosteroids and mania: A systematic review. World J Biol Psychiatry. March 2024. doi:10.1080/15622975.2024.2312572 · PMID 38363330
32. Journal / agency Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Hormone Research. November 2009. doi:10.1159/000229762 · PMID 19940494
33. Other Steroid Drug Withdrawal Symptoms, Treatment & Prognosis
34. Other Bello CS, Garrett SD. Therapeutic and Adverse Effects of Glucocorticoids
35. Journal / agency Iliopoulou A, Abbas A, Murray R. How to manage withdrawal of glucocorticoid therapy. Prescriber. 19 May 2013. doi:10.1002/psb.1060
36. Journal / agency Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesthesia Progress. Spring 2013. doi:10.2344/0003-3006-60.1.25 · PMID 23506281 · PMC3601727
37. Harm reduction site Prednisone
38. Journal / agency Prednisone
39. Journal / agency Schijvens AM, Ter Heine R, de Wildt SN, Schreuder MF. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatric Nephrology. March 2019. doi:10.1007/s00467-018-3929-z · PMID 29549463 · PMC6349812
40. Other Wan Y. Delayed-release prednisone (Lodotra™) approved in EU for treatment of rheumatoid arthritis. 8 January 2009
41. Journal / agency Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. January 2008. doi:10.1016/S0140-6736(08)60132-4 · PMID 18207016
42. Journal / agency Tak LM, Rosmalen JG. Dysfunction of stress responsive systems as a risk factor for functional somatic syndromes. J Psychosom Res. May 2010. doi:10.1016/j.jpsychores.2009.12.004 · PMID 20403505
43. Journal / agency Karvelas D, Vasudevan SV. Fibromyalgia syndrome. Pain Manag. November 2011. doi:10.2217/pmt.11.55 · PMID 24645767
44. Journal / agency Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. October 1985. PMID 3910836
45. Journal / agency Wainwright M. The secret of success: Arthur Nobile's discovery of the steroids prednisone and prednisolone in the 1950s revolutionised the treatment of arthritis. Chemistry in Britain. 1998
46. Other Inventor Profile: Arthur Nobile
47. Other Arthur Nobile
48. Other Merck Index. 2006
49. Journal / agency Herzog HL, Nobile A, Tolksdorf S, Charney W, Hershberg EB, Perlman PL. New antiarthritic steroids. Science. February 1955. doi:10.1126/science.121.3136.176 · PMID 13225767
50. Journal / agency Meticorten: FDA-Approved Drugs
51. Journal / agency Delta-Cortef: FDA-Approved Drugs

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.